Liraglutide vs Semaglutide

Overview

Liraglutide and semaglutide are both GLP-1 receptor agonists developed by Novo Nordisk, representing successive generations of incretin therapy. Liraglutide requires daily injection, while semaglutide offers weekly dosing and greater efficacy. Both are FDA-approved for type 2 diabetes and obesity.

This comparison illustrates the evolution of GLP-1 therapeutics and helps understand the practical differences between these related medications.

Key Facts

Aspect	Liraglutide	Semaglutide
Developer	Novo Nordisk	Novo Nordisk
Approval Year	2010 (diabetes)	2017 (diabetes)
Mechanism	GLP-1 receptor agonist	GLP-1 receptor agonist
Brands (Diabetes)	Victoza	Ozempic
Brands (Obesity)	Saxenda	Wegovy

Structure Comparison

Aspect	Liraglutide	Semaglutide
Homology to GLP-1	97%	94%
Amino Acid Changes	1 (Lys34→Arg)	2 (Ala8→Aib, Lys34→Arg)
Fatty Acid Chain	C16 (palmitic acid)	C18 diacid chain
Half-life	~13 hours	~165 hours (~7 days)

Why Semaglutide Lasts Longer

• Aib substitution at position 8 resists DPP-4 degradation
• C18 fatty acid chain enhances albumin binding
• Slower release from albumin reservoir
• Allows weekly dosing vs. daily

Efficacy Comparison

Weight Loss

Metric	Liraglutide 3mg	Semaglutide 2.4mg
Trial	SCALE	STEP 1
Mean Weight Loss	-8.0%	-14.9%
≥5% Weight Loss	63%	86%
≥10% Weight Loss	33%	69%
≥15% Weight Loss	14%	50%

Note: Semaglutide achieves nearly double the weight loss of liraglutide in clinical trials.

HbA1c Reduction

Metric	Liraglutide 1.8mg	Semaglutide 1mg
Reduction	-1.1% to -1.5%	-1.5% to -1.8%
Target under 7%	~60%	~70-80%

Head-to-Head Trial (SUSTAIN 10)

Direct comparison in type 2 diabetes:

Outcome	Semaglutide 1mg	Liraglutide 1.2mg
HbA1c Change	-1.7%	-1.0%
Weight Change	-5.8 kg	-1.9 kg
Superiority	Yes	—

Administration Comparison

Aspect	Liraglutide	Semaglutide (Injectable)
Injections/month	~30	4
Flexibility	Any time of day	Same day each week

Oral Semaglutide Option

Aspect	Liraglutide	Oral Semaglutide (Rybelsus)
Route	Injection only	Oral tablet
Food Restriction	None	Fasting required

Cardiovascular Evidence

Aspect	Liraglutide	Semaglutide
CV Trial	LEADER	SUSTAIN-6, SELECT
MACE Reduction	13%	26% (SUSTAIN-6), 20% (SELECT)
CV Death	22% reduction	Significant reduction
FDA CV Indication	Yes	Yes

Cardiovascular Summary

Both medications have demonstrated cardiovascular benefit:

Outcome	Liraglutide	Semaglutide
Heart Attack	Reduced	Reduced
Stroke	Reduced	Reduced
CV Death	Reduced	Reduced
Heart Failure	Neutral	Preliminary benefit

Side Effect Comparison

Gastrointestinal Effects

Effect	Liraglutide	Semaglutide
Nausea	30-40%	30-45%
Vomiting	10-15%	15-25%
Diarrhea	15-20%	20-30%
Constipation	10-15%	15-20%

Note: Semaglutide’s higher efficacy comes with somewhat higher GI side effect rates.

Discontinuation Rates

Reason	Liraglutide	Semaglutide
GI Side Effects	6-10%	7-10%
Overall	8-12%	8-12%

Other Side Effects

Effect	Liraglutide	Semaglutide
Injection Site	Occasional	Less frequent (weekly)
Hypoglycemia	Low (monotherapy)	Low (monotherapy)
Pancreatitis	Rare	Rare
Gallbladder Events	Elevated risk	Elevated risk

Indications Comparison

Indication	Liraglutide	Semaglutide
Type 2 Diabetes	Victoza (FDA)	Ozempic (FDA)
Obesity (BMI ≥30)	Saxenda (FDA)	Wegovy (FDA)
Overweight + Comorbidity	Saxenda (FDA)	Wegovy (FDA)
CV Risk Reduction	Victoza (FDA)	Ozempic (FDA)

Cost Comparison

Factor	Liraglutide	Semaglutide
List Price	~$1,000-1,400/month	~$900-1,350/month
Insurance Coverage	Established	Expanding
Generic Available	No	No

Note: Actual costs vary significantly based on insurance, pharmacy, and dosage.

Patient Selection Considerations

Liraglutide May Be Preferred When:

• Daily routine is already injection-based
• Shorter half-life desired (e.g., pregnancy planning)
• Established comfort with the medication
• Insurance/cost factors favor it

Semaglutide May Be Preferred When:

• Weekly dosing strongly preferred
• Maximum efficacy is priority
• Oral option desired (Rybelsus)
• Greater weight loss needed

Evidence Quality

Factor	Liraglutide	Semaglutide
Trial Quality	High	High
Sample Size	Large	Large
Long-term Data	10+ years	5+ years
Real-World Evidence	Extensive	Growing rapidly
CV Outcomes	LEADER (proven)	SELECT (proven)

Summary

Factor	Liraglutide	Semaglutide
Weight Loss	~8%	~15%
HbA1c Reduction	~1.3%	~1.7%
CV Benefit	Proven	Proven
Oral Option	No	Yes (Rybelsus)
Track Record	Longer	Shorter

Key Takeaways

1. Semaglutide is more effective: Nearly double the weight loss, better glycemic control
2. Semaglutide is more convenient: Weekly vs. daily dosing
3. Both have CV benefit: Proven cardiovascular risk reduction
4. Semaglutide has oral option: Rybelsus available for those preferring tablets
5. Liraglutide has longer track record: More years of real-world data
6. GI effects similar: Both cause nausea, vomiting, diarrhea
7. Cost is similar: Both remain expensive branded medications
8. Same developer: Both from Novo Nordisk, representing generational evolution

---

This comparison is for educational purposes only. Both medications are FDA-approved. Consult a healthcare provider for treatment decisions.